Effect of subthalamic nucleus deep brain stimulation on driving in Parkinson disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 17, 2013
- Accepted in final form September 23, 2013
- First Published December 18, 2013.
Article Versions
- Previous version (December 18, 2013 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Carsten Buhmann, MD,
- Lea Maintz,
- Jonas Hierling,
- Eik Vettorazzi,
- Christian K.E. Moll, MD,
- Andreas K. Engel, MD,
- Christian Gerloff, MD,
- Wolfgang Hamel, MD and
- Wolfgang H. Zangemeister, MD
- Carsten Buhmann, MD,
(1)GSK, (2)UCB Pharma
NONE
(1) GSK, funding for speaker honoraria, (2) Medtronic, funding for speaker honoraria, (3) Orion Pharma, funding for speaker honoraria, (4) UCB, funding for speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Georg & J�rgen Rickertsen Stiftung Hamburg
NONE
NONE
NONE
NONE
NONE
NONE
- Lea Maintz,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonas Hierling,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eik Vettorazzi,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian K.E. Moll, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas K. Engel, MD,
NONE
NONE
NONE
Associate Editor of �Frontiers in Integrative Neuroscience�, Associate Editor of �Frontiers in Consciousness Research�, Advisory Editorial Board member of �Trends in Cognitive Sciences�, Advisory Editorial Board member of �Consciousness and Cognition�, Advisory Editorial Board member of �Experimental Brain Research�
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
DFG, SFB 936, EU, FP7-ICT-270212, EU, ERC-2010-AdG-269716
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Gerloff, MD,
(1) Bayer Vital, (2) Boehringer Ingelheim, (3) EBS technologies, (4) Silk Road Medical
NONE
(1) Bayer Vital, (2) Boehringer Ingelheim, (3) Biogen Idec, (4) ev3/Covidien, (5) Glaxo Smith Kline, (6) Grifols, (7) Inomed, (8) Lundbeck, (9) Nexstim, (10) Pfizer, (11) Sanofi Aventis, (12) UCB, (13) Merck Serono
(1) INFO Neurology Psychatrie, (2) Aktuelle Neurologie, (3) Editor of Textbook “Therapie und Verlauf neurologischer Erkrankungen”
NONE
NONE
NONE
(1) EBS Technologies (2) Silk Road Medical
NONE
NONE
NONE
(1) Merz Pharmaceuticals*, (2) Allergan*, (3) Novartis*, (4) NeuroConn**all grants were supporting employees/scientists of my clinic (no direct support of myself)
(1) DFG: SFB 936, since 2011, ongoing, (2) BMBF/DFG NETS Trial, ongoing, (3) EU FP7: project grant WAKE-UP stroke trial, since 2011, ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Hamel, MD and
NONE
NONE
Speaker honoraria, funding for travel or consulting honoraria from Medtronic, St. Jude, Boston Scientific, Synaptix
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang H. Zangemeister, MD
NONE
NONE
NONE
JEMR - Journal of eye movement research, editorial, advisory board member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Rickertsen Stiftung Hamburg
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Neurology (C.B., L.M., J.H., C.G., W.H.Z.), Medical Biometry and Epidemiology (E.V.), Neurophysiology and Pathophysiology (C.K.E.M., A.K.E.), and Neurosurgery (W.H.), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Correspondence to Priv.-Doz. Dr. Buhmann: buhmann{at}uke.uni-hamburg.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson diseaseA. Sailer, D. I. Cunic, G. O. Paradiso et al.Neurology, January 29, 2007 -
Views and Reviews
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PDR.J. St. George, J.G. Nutt, K.J. Burchiel et al.Neurology, October 04, 2010 -
Expedited Publication
Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's diseaseR. Kumar, A. M. Lozano, Y. J. Kim et al.Neurology, September 01, 1998 -
Articles
Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulationR. Kumar, A.M. Lozano, E. Sime et al.Neurology, August 01, 1999